Skin Cancers | Clinical

June 17, 2022

A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.

June 06, 2022

Results from the RELATIVITY-047 trial showed improved progression-free survival for patients with advanced melanoma who received nivolumab plus relatlimab.

May 26, 2022

In an interview with Targeted Oncology following the tweet chat, Omid A. Hamid, MD, discussed the key takeaways from the discussion, including the ways he would treat the patient discussed in the case.

May 25, 2022

Valencia Thomas, MD, MHCM, discusses how the management of care for patients with non-melanoma skin cancers has changed over the past decade.

May 19, 2022

For military veterans, future research should be accompanied by systematic efforts to improve skin cancer prevention, treatment, and outcomes among military service members and veterans, according to Carolyn J. Heckman, PhD.

May 16, 2022

New and emerging treatment modalities for advanced nonmelanoma skin cancer provide hope for this patient subset.

May 05, 2022

The phase 3 COMBI-i trial demonstrated that spartalizumab plus dabrafenib and trametinib has modest efficacy in BRAF V600-positive metastatic melanoma, but no progression-free survival benefit when compared with dabrafenib and trametinib alone.

April 25, 2022

Valencia Thomas, MD, MHCM, discusses the current landscape regarding non-melanoma skin cancers.

April 21, 2022

For advanced melanoma that is resistant to anti–PD-1 therapies, the addition of BO-112 to pembrolizumab appears to be effective and safe.

April 20, 2022

Valencia D. Thomas, MD, discussed managing patients with aggressive non-melanoma skin cancers with the emergence of new treatment options and technology.